Trial Profile

Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trebananib (Primary) ; Bevacizumab
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Jun 2017 Status changed from active, no longer recruiting to completed.
20 Apr 2017 Planned end date has been changed from 1 Dec 2016 to 1 May 2017
02 Feb 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com